RXi Pharmaceuticals Corp. (NASDAQ: RXII) is a biotechnology company focused on discovering and developing innovative therapeutics, primarily in the areas of dermatology and ophthalmology, addressing high-unmet medical needs. The company’s discovery and clinical development programs are based on siRNA technology as well as immunotherapy agents.  These compounds include, but are not limited to, RXi’s proprietary, self-delivering RNAi (sd-rxRNA) compounds for the treatment of dermal and retinal scarring. RXi’s robust pipeline, coupled with an extensive patent portfolio, provides for product and business development opportunities across a broad spectrum. For more information, visit the company’s website at www.rxipharma.com